|
|
|
| home > ict > Summer 2018 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
|
 |
| |
|
|
|
|
|
Regulatory Guidance on Outsourcing
Organising Outsourcing
Martin Robinson at IAOCR delves into the world of outsourcing as a part of clinical trials and provides a detailed account of how to receive advice and guidance through regulatory bodies.
|
|
|
|
Dealing with Data Protection
Protecting Privacy
ICT spoke to Dr Andrew Rut at MyMeds&Me to discuss the all-important topic of patient data safety during clinical trials and the ways in which this sensitive issue should be approached.
|
|
|
|
|
Q&A: Clinical Trial Transparency
Patient Privacy
ICT spoke to Thomas Wicks and Francine Lane at TrialScope about noncompliance, the risks and penalties it can lead to, and how to avoid running afoul of regulators.
|
|
|
|
|
Improving the Clinical Trial Continuum
Perfecting Practices
Investments in new technologies to increase performances, gain greater quality, and encourage optimisation across trials are some of the most pressing topics for companies. Craig Morgan at goBalto provides an insight.
|
|
|
|
|
Event Preview
Let’s Get Clinical
Get a taste of what to expect in this event preview if visiting Partnerships in Clinical Trials Europe this November, including one-to-one meetings, digital partnering, and networking with industry leaders from around the globe.
|
|
|
|
|
|
Using Gamification and Behavioural Economics in Surveys
Gaining from Gamification
Creating a questionnaire for clinical trials can be fraught with difficulties, particularly when attempting to extract as much data as possible from respondents. Dr Keith Meadows at Health Outcome Solutions provides a clearer answer.
|
|
|
|
Translation and Comprehension of Disease Activity
PRO Translation
Language barriers and translation issues when using patient-recorded outcomes over a multinational patient group are an essential consideration. The team at RWS Life Sciences tell us more.
|
|
|
|
Site Engagement Technology
Appreciated and Informed
Using different scenarios to promote the use of site engagement technology, Dani Darasz and Lesley Freese at DrugDev comment on how clean trial data and protocol adherence can be greatly improved.
|
|
|
|
|
|
Q&A: Partnerships in Clinical Trials Europe
Clinical Connections
With the upcoming Partnerships in Clinical Trials Europe event in November quickly approaching, ICT spoke to Louisa Maitland about what visitors can expect from the main streams.
|
|
|
|
|
Robust Insurance Policies
Navigating Global Complexities
Kathryn Moon at Gallagher sheds some light on key insurance considerations, as deciding on a specific insurance policy can be one of the great difficulties a company faces when conducting clinical trials.
|
|
|
|
Clinical Trials Liability Insurance
A Safety Net
Designed to excel if issues arise during any clinical trial, insurance is an essential and continuously evolving entity. Hanna Beaumont at La Playa explains some of the associated complexities in the industry.
|
|
|
|
|
|
Current Trends in Outsourcing
Outsourcing Evolution
Outsourcing has been ongoing in the pharmaceutical industry for many years, but, as the methods develop, which is the right approach? Colin Stanley at ICON Functional Services explains.
|
|
|
|
Functional Outsourcing Versus Full-Service Partnerships
Strategic Selection
Jeff Mayhew and Elizabeth Koury at LabConnect describe the top factors that companies should examine when selecting a strategic partner for assistance in clinical trials.
|
|
|
|
|
End Point
Restricting Remedies
ICT’s Editor Dr Graham Hughes surveys the differing regulations regarding cannabis between the US and UK.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Blood Tests May Prevent Relapse in Breast Cancer Patients
The Royal Marsden NHS Foundation Trust is leading an international
research collaboration to offer blood tests that can identify risk of
relapse in breast cancer patients. The trial will assess whether
personalised blood tests can show which patients will relapse, years
before it’s shown on a scan - treatment can then be altered to try and
prevent relapse from happening. There are currently no effective tests
to establish which patients are at risk of relapse after previous
treatment for breast cancer.
More info >> |
|
 |
White Papers |
 |
|
Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences
CIDP (Centre International de Développement Pharmaceutique)
Mauritius, the tropical island situated in the Indian Ocean and known
worldwide for its beautiful beaches, is also internationally recognised
for its rule of law, and political and social stability. Over the past
few years, the economy has been successfully transitioned from a
monocrop to a diversified innovation-driven and knowledge-based economy,
resting on agribusiness, export-oriented manufacturing, tourism,
financial services, property development and real estate, ICT-BPO, the
seafood industry, a free port, logistics and a nascent ocean economy.
Emerging sectors such as healthcare and life sciences are presenting
some niche areas for the taking, and the enabling environment is being
put in place to make it happen - especially in the light of sustained
growth within pharmaceutical, medical device, and clinical research.
Important
international players are already in operation locally as the country
has established the appropriate legal and regulatory frameworks based on
international norms, for the development of a strong biomedical
research sector.
More info >> |
|
|
